Loading...
Many patients with stable coronary artery disease (CAD) treated with both aspirin and statins continue to have elevated levels of biomarkers of inflammation, including high-sensitivity C-reactive protein (hs-CRP), which are predictive of future vascular events. Might colchicine, a safe and effective anti-inflammatory agent, lower hs-CRP in such patients? Researchers in Australia investigated this issue in 200 ambulatory patients with stable CAD who were taking both aspirin and high-dose atorvastatin, of whom 64 (32%) had hs-CRP levels >2 mg/L. For 20 of these patients, therapy continued unchanged, and hs-CRP was measured again at 2 weeks. Low-dose colchicine (0.5 mg twice daily) was added to the usual therapy of the remaining 44 patients fo…